Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Comparison of anti-atopic dermatitis activities between DHMEQ and tacrolimus ointments in mouse model without stratum corneum.

He H, Gao X, Wang X, Li X, Jiang X, Xie Z, Ma K, Ma J, Umezawa K, Zhang Y.

Int Immunopharmacol. 2019 Mar 13;71:43-51. doi: 10.1016/j.intimp.2019.03.015. [Epub ahead of print]

PMID:
30877873
2.

External application of NF-κB inhibitor DHMEQ suppresses development of atopic dermatitis-like lesions induced with DNCB/OX in BALB/c mice.

Jiang X, Lan Y, Wei B, Dai C, Gu Y, Ma J, Liu X, Umezawa K, Zhang Y.

Immunopharmacol Immunotoxicol. 2017 Jun;39(3):157-164. doi: 10.1080/08923973.2017.1312436.

PMID:
28418286
3.

Dehydroxymethylepoxyquinomicin suppresses atopic dermatitis-like lesions in a stratum corneum-removed murine model through NF-κB inhibition.

Jiang X, He H, Xie Z, Wen H, Li X, Li X, Ma J, Umezawa K, Zhang Y.

Immunopharmacol Immunotoxicol. 2019 Feb 6:1-8. doi: 10.1080/08923973.2018.1510962. [Epub ahead of print]

PMID:
30724631
4.
5.

Topically applied semaphorin 3A ointment inhibits scratching behavior and improves skin inflammation in NC/Nga mice with atopic dermatitis.

Negi O, Tominaga M, Tengara S, Kamo A, Taneda K, Suga Y, Ogawa H, Takamori K.

J Dermatol Sci. 2012 Apr;66(1):37-43. doi: 10.1016/j.jdermsci.2012.01.007. Epub 2012 Jan 21.

PMID:
22381253
6.

Tacrolimus ointment. A review of its therapeutic potential as a topical therapy in atopic dermatitis.

Cheer SM, Plosker GL.

Am J Clin Dermatol. 2001;2(6):389-406. Review.

PMID:
11770393
7.

A Role of Staphyococcus aureus, Interleukin-18, Nerve Growth Factor and Semaphorin 3A, an Axon Guidance Molecule, in Pathogenesis and Treatment of Atopic Dermatitis.

Ikezawa Z, Komori J, Ikezawa Y, Inoue Y, Kirino M, Katsuyama M, Aihara M.

Allergy Asthma Immunol Res. 2010 Oct;2(4):235-46. doi: 10.4168/aair.2010.2.4.235. Epub 2010 May 12.

8.

Tacrolimus nanoparticles based on chitosan combined with nicotinamide: enhancing percutaneous delivery and treatment efficacy for atopic dermatitis and reducing dose.

Yu K, Wang Y, Wan T, Zhai Y, Cao S, Ruan W, Wu C, Xu Y.

Int J Nanomedicine. 2017 Dec 22;13:129-142. doi: 10.2147/IJN.S150319. eCollection 2018.

9.

Tacrolimus ointment 0.03% is safe and effective for the treatment of mild to moderate atopic dermatitis in pediatric patients: results from a randomized, double-blind, vehicle-controlled study.

Schachner LA, Lamerson C, Sheehan MP, Boguniewicz M, Mosser J, Raimer S, Shull T, Jaracz E; US Tacrolimus Ointment Study Group.

Pediatrics. 2005 Sep;116(3):e334-42.

PMID:
16140675
10.

7,8,4'-Trihydroxyisoflavone attenuates DNCB-induced atopic dermatitis-like symptoms in NC/Nga mice.

Kim H, Kim JR, Kang H, Choi J, Yang H, Lee P, Kim J, Lee KW.

PLoS One. 2014 Aug 29;9(8):e104938. doi: 10.1371/journal.pone.0104938. eCollection 2014.

11.

Dermatophagoides farinae extract induces severe atopic dermatitis in NC/Nga mice, which is effectively suppressed by the administration of tacrolimus ointment.

Oshio T, Sasaki Y, Funakoshi-Tago M, Aizu-Yokota E, Sonoda Y, Matsuoka H, Kasahara T.

Int Immunopharmacol. 2009 Apr;9(4):403-11. doi: 10.1016/j.intimp.2008.12.013. Epub 2009 Jan 20.

PMID:
19162238
12.

[Pharmacological profile and clinical effect of tacrolimus ointment (Protopic ointment) for atopic dermatitis].

Hiroi J.

Nihon Yakurigaku Zasshi. 2001 May;117(5):351-7. Review. Japanese.

PMID:
11411345
13.

Wet-wrap treatment using dilutions of tacrolimus ointment and fluticasone propionate cream in human APOC1 (+/+) mice with atopic dermatitis.

Oranje AP, Verbeek R, Verzaal P, Haspels I, Prens E, Nagelkerken L.

Br J Dermatol. 2009 Jan;160(1):54-61. doi: 10.1111/j.1365-2133.2008.08834.x. Epub 2008 Sep 15.

PMID:
18795918
14.

Tacrolimus ointment: a new therapy for atopic dermatitis--review of the literature.

Pustisek N, Lipozencić J, Ljubojević S.

Acta Dermatovenerol Croat. 2002 Mar;10(1):25-32. Review.

PMID:
12137728
15.

Three times weekly tacrolimus ointment reduces relapse in stabilized atopic dermatitis: a new paradigm for use.

Paller AS, Eichenfield LF, Kirsner RS, Shull T, Jaracz E, Simpson EL; US Tacrolimus Ointment Study Group.

Pediatrics. 2008 Dec;122(6):e1210-8. doi: 10.1542/peds.2008-1343. Epub 2008 Nov 17.

PMID:
19015204
16.

Total sesquiterpene lactones isolated from Inula helenium L. attenuates 2,4-dinitrochlorobenzene-induced atopic dermatitis-like skin lesions in mice.

Wang Q, Gao S, Wu GZ, Yang N, Zu XP, Li WC, Xie N, Zhang RR, Li CW, Hu ZL, Zhang WD.

Phytomedicine. 2018 Jul 15;46:78-84. doi: 10.1016/j.phymed.2018.04.036. Epub 2018 Apr 19.

PMID:
30097125
17.

Differences in therapeutic effects of topically applied corticosteroid and tacrolimus on atopic dermatitis-like symptoms in NC/Nga mice.

Noguchi A, Tominaga M, Takahashi N, Matsuda H, Kamata Y, Umehara Y, Ko KC, Suga Y, Ogawa H, Takamori K.

J Dermatol Sci. 2017 Apr;86(1):54-62. doi: 10.1016/j.jdermsci.2016.12.015. Epub 2016 Dec 24.

PMID:
28069324
19.

Tacrolimus ointment causes inflammatory dendritic epidermal cell depletion but no Langerhans cell apoptosis in patients with atopic dermatitis.

Schuller E, Oppel T, Bornhövd E, Wetzel S, Wollenberg A.

J Allergy Clin Immunol. 2004 Jul;114(1):137-43.

PMID:
15241357
20.

[Effect of topical tacrolimus ointment on expression of Toll-like receptors 2 and 4 in lesional atopic dermatitis skin].

Xie ZQ, Liu LL, Yang GY, Zhu XJ.

Beijing Da Xue Xue Bao Yi Xue Ban. 2006 Aug 18;38(4):420-3. Chinese.

Supplemental Content

Support Center